**BHAGERIA & JAJODIA PHARMACEUTICALS PRIVATE LIMITED**

**UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED DECEMBER 31, 2025**

**(Rs. in Lakhs)**

| | PARTICULARS | Quarter Ended | | | Nine Months Ended | | Year Ended |
|---|---|---|---|---|---|---|---|
| | | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| | | 31-12-2025 | 30-09-2025 | 31-12-2024 | 31-12-2025 | 31-12-2024 | 31-03-2025 |
| 1 | **Revenue from operations (Net of GST)** | 15.91 | 49.11 | 286.91 | 191.95 | 417.47 | 618.57 |
| 2 | **Other income** | 1.99 | 2.28 | 2.13 | 6.37 | 5.78 | 7.95 |
| 3 | **Total Income (1+2)** | **17.90** | **51.39** | **289.03** | **198.32** | **423.25** | **626.52** |
| 4 | **Expenses** | | | | | | |
| | Cost of materials consumed | - | - | - | | - | - |
| | Purchase of Stock-in-Trade | 54.78 | 86.08 | 411.76 | 319.80 | 547.05 | 851.69 |
| | Changes in inventories of finished goods, work-in-progress and Stock-in-Trade | - | - | - | | - | - |
| | Employee benefit expense | 1.51 | 0.56 | - | 2.07 | - | - |
| | Finance costs | 31.28 | 28.36 | 31.93 | 87.49 | 86.31 | 115.93 |
| | Depreciation and amortization expense | - | - | - | | - | - |
| | Other expenses | 1.37 | 1.14 | 1.43 | 3.61 | 7.11 | 8.65 |
| | **Total expenses** | **88.94** | **116.14** | **445.12** | **412.96** | **640.47** | **976.27** |
| 5 | **Profit before tax (3-4)** | **(71.04)** | **(64.75)** | **(156.09)** | **(214.63)** | **(217.22)** | **(349.75)** |
| 6 | **Tax expense:** | - | - | - | - | - | - |
| | Current tax | - | | - | - | - | |
| | Deferred tax | - | | - | - | - | |
| | (Excess) / Short Provision for tax | - | | - | - | - | |
| 7 | **Profit for the period (5-6)** | **(71.04)** | **(64.75)** | **(156.09)** | **(214.63)** | **(217.22)** | **(349.75)** |
| 8 | **Other comprehensive income** | | | | | | |
| | Items that will not be reclassified to profit or loss | | | | | | |
| | i. Remeasurement of the defined benefit plans | - | - | - | - | - | - |
| | ii. Income tax relating to items that will not be reclassified to profit or loss | - | - | - | - | - | - |
| | **Total other comprehensive income for the period (net of tax)(i+ii)** | - | - | - | - | - | - |
| 9 | **Total Comprehensive Income for the period (7+8)** | **(71.04)** | **(64.75)** | **(156.09)** | **(214.63)** | **(217.22)** | **(349.75)** |
| 10 | **Paid up Capital** | | | | | | |
| | Face value of share (Rs.) | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| 11 | Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year | - | - | - | - | - | - |
| 12 | **Earnings per equity share (EPS) :** | | | | | | |
| | Basic EPS (Rs) (not annualised) | (14.21) | (12.95) | (31.22) | (429.27) | (434.44) | (69.95) |
| | Diluted EPS (Rs) (not annualised) | (14.21) | (12.95) | (31.22) | (429.27) | (434.44) | (69.95) |
| | Face value of share (Rs) | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |